Cancer Immunotherapy

Dendritic Cell Vaccine Evaluated in Advanced Melanoma Patients

Published in Vaccine Weekly, September 27th, 2000

Researchers in Italy evaluated a vaccine protocol based on dendritic cells (DC) pulsed with heat shock protein (HSP) or lysate from autologous tumor in patients with advanced melanoma.

"A vaccination protocol for advanced melanoma and renal cell carcinoma with DC pulsed with HSP obtained from autologous tumor tissue was planned in the Department of Medical Oncology, Forli," reported Angela Riccobon and colleagues from Pierantoni Hospital and the Institute Oncologico Romagnolo. "DC were differentiated from peripheral blood lymphocytes (PBL) obtained by leukapheresis without pharmacological stimulation immediately before the first treatment cycle."

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2000-09-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry